Drug-induced diarrhea associated with antineoplastic drugs

Abstract

Diarrhea is the most common adverse reaction of anticancer drugs, as well as radiation therapy of the pelvic organs or abdominal cavity: the incidence of diarrhea of different seveity reaches 80% during chemotherapy and / or radiation therapy; one third of these patients develop severe diarrhea (3^rd or 4^th degree). Most often, drug-induced diarrhea occurs during chemotherapy, using 5-fluorouracil or irinotecan, taking new anticancer drugs from the classes of checkpoint inhibitors, monoclonal antibodies, tyrosine kinase inhibitors. The most common mechanisms underlying the development of drug-induced diarrhea are damage to the intestinal mucosa, impaired absorption of proteins, carbohydrates, fats, inflammation, a perverse immune response, microflora imbalance, and others.

Algorithms for the management of patients with severe diarrhea include suspension (grade 1-2, 3) or complete cessation (grade 4, grade 3) of the use of an antineoplastic agent – an inducer, prescribing drugs that reduce intestinal motility (loperamide) while excluding the infectious nature of diarrhea, intravenous methylprednisolone (for example, diarrhea caused by monoclinal antibodies in the absence of suspicion of potential bowel perforation). In cases where drug-induced diarrhea lasts more than 48 hours, or a patient reports symptoms of dehydration, or a fever occurs, urgent hospitalization is necessary.

The objective of this review is to analyze scientific literature data on the prevalence, pathophysiological mechanisms and risk factors for the development of diarrhea associated with the intake of anticancer drugs, as well as its prevention and treatment.

Keywords

antineoplastic drugs / diarrhea / drug-induced diarrhea / adverse drug reactions / chemotherapy

References

[1] Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918–2926. DOI: 10.1200/JCO.2004.04.132

[2] Benson A.B. 3rd, Ajani J.A., Catalano R.B. et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea // J. Clin. Oncol. 2004. Vol. 22, No. 14. P. 2918–2926. DOI: 10.1200/JCO.2004.04.132

[3] Sanguineti G, Endres EJ, Parker BC, et al. Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer. Acta Oncol. 2008;47(2):301–310. DOI: 10.1080/02841860701558849

[4] Sanguineti G., Endres E.J., Parker B.C. et al. Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer // Acta. Oncol. 2008. Vol. 47, No. 2. P. 301–310. DOI: 10.1080/02841860701558849

[5] Maroun JA, Anthony LB, Blais N, et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol. 2007;14(1):13–20. DOI: 10.3747/co.2007.96

[6] Maroun J.A., Anthony L.B., Blais N. et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea // Curr. Oncol. 2007. Vol. 14, No. 1. P. 13–20. DOI: 10.3747/co.2007.96

[7] Bossi P, Antonuzzo A, Cherny NI, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv126–iv142. DOI: 10.1093/annonc/mdy145

[8] Bossi P., Antonuzzo A., Cherny N.I. et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines // Ann. Oncol. 2018. Vol. 29, No. Suppl 4. P. iv126–iv142. DOI: 10.1093/annonc/mdy145

[9] Antonuzzo A, Lucchesi M, Brunetti IM, et al. Supportive care and not only palliative care in the route of cancer patients. Support Care Cancer. 2013;21(3):657–658. DOI: 10.1007/s00520-012-1658-6

[10] Antonuzzo A., Lucchesi M., Brunetti I.M. et al. Supportive care and not only palliative care in the route of cancer patients // Support Care Cancer. 2013. Vol. 21, No. 3. P. 657–658. DOI: 10.1007/s00520-012-1658-6

[11] Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15(10):447–460. DOI: 10.1016/S1470-2045(14)70006-3

[12] Andreyev J., Ross P., Donnellan C. et al. Guidance on the management of diarrhoea during cancer chemotherapy // Lancet Oncol. 2014. Vol. 15, No. 10. P. 447–460. DOI: 10.1016/S1470-2045(14)70006-3

[13] Dunberger G, Lind H, Steineck G, et al. Loose stools lead to fecal incontinence among gynecological cancer survivors. Acta Oncol. 2011;50(2):233–242. DOI: 10.3109/0284186X.2010.535013

[14] Dunberger G., Lind H., Steineck G. et al. Loose stools lead to fecal incontinence among gynecological cancer survivors // Acta Oncol. 2011. Vol. 50, No. 2. P. 233–242. DOI: 10.3109/0284186X.2010.535013

[15] Dunberger G, Lind H, Steineck G, et al. Self-reported symptoms of faecal incontinence among long-term gynaecological cancer survivors and population-based controls. Eur J Cancer. 2010;46(3):606–615. DOI: 10.1016/j.ejca.2009.10.023

[16] Dunberger G., Lind H., Steineck G. et al. Self-reported symptoms of faecal incontinence among long-term gynaecological cancer survivors and population-based controls // Eur. J. Cancer. 2010. Vol. 46, No. 3. P. 606–615. DOI: 10.1016/j.ejca.2009.10.023

[17] Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract. 2007;13(4):181–198. DOI: 10.1177/1078155207077335

[18] Richardson G., Dobish R. Chemotherapy induced diarrhea // J. Oncol. Pharm. Pract. 2007. Vol. 13, No. 4. P. 181–198. DOI: 10.1177/1078155207077335

[19] Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer. 2006;14(9):890–900. DOI: 10.1007/s00520-006-0040-y

[20] Gibson R.J., Keefe D.M. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies // Support Care Cancer. 2006. Vol. 14, No. 9. P. 890–900. DOI: 10.1007/s00520-006-0040-y

[21] Andreyev HJ, Davidson SE, Gillespie C, et al. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut. 2012;61(2):179–192. DOI: 10.1136/gutjnl-2011-300563

[22] Andreyev H.J., Davidson S.E., Gillespie C. et al. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer // Gut. 2012. Vol. 61, No. 2. P. 179–192. DOI: 10.1136/gutjnl-2011-300563

[23] Wei D, Heus P, van de Wetering FT, et al. Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer. Cochrane Database Syst Rev. 2018;8(8):CD008831. DOI: 10.1002/14651858.CD008831.pub3

[24] Wei D., Heus P., van de Wetering F.T. et al. Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer // Cochrane Database Syst. Rev. 2018. Vol. 8, No. 8. P. CD008831. DOI: 10.1002/14651858.CD008831.pub3

[25] Miller L. Guidelines for Management of Systemic Anti-Cancer Therapy (SACT) induced diarrhoea in adult haematology and oncology patients [Internet]. Available from: https://www.nhsscotlandnorth.scot/uploads/tinymce/NCA/SACT %20Guidelines/NOS-STG-003_ %20diarrhoea_version %202.pdf. Accessed: Aug 12, 2021.

[26] Miller L. Guidelines for Management of Systemic Anti-Cancer Therapy (SACT) induced diarrhoea in adult haematology and oncology patients [Электронный ресурс]. Режим доступа: https://www.nhsscotlandnorth.scot/uploads/tinymce/NCA/SACT %20Guidelines/NOS-STG-003_ %20diarrhoea_version %202.pdf. Дата обращения: 12.08.2021.

[27] Common Terminology Criteria for Adverse Events (CTCAE). Version 5 ed. U.S. [Internet]. Department of Health and Human Services. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed: Aug 12, 2021.

[28] Common Terminology Criteria for Adverse Events (CTCAE). Version 5 ed. U.S. [Электронный ресурс] // Department of Health and Human Services. Режим доступа: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Дата обращения: 12.08.2021.

[29] Verhaar S, Vissers PA, Maas H, et al. Treatment-related differences in health related quality of life and disease specific symptoms among colon cancer survivors: results from the population-based PROFILES registry. Eur J Cancer. 2015;51(10):1263–1273. DOI: 10.1016/j.ejca.2015.04.004

[30] Verhaar S., Vissers P.A., Maas H. et al. Treatment-related differences in health related quality of life and disease specific symptoms among colon cancer survivors: results from the population-based PROFILES registry // Eur. J. Cancer. 2015. Vol. 51, No. 10. P. 1263–1273. DOI: 10.1016/j.ejca.2015.04.004

[31] Parnes HL, Fung E, Schiffer CA. Chemotherapy-induced lactose intolerance in adults. Cancer. 1994;74(5):1629–1633. DOI: 10.1002/ 1097-0142(19940901)74:5<1629::aid-cncr2820740523>3.0.co;2-l

[32] Parnes H.L., Fung E., Schiffer C.A. Chemotherapy-induced lactose intolerance in adults // Cancer. 1994. Vol. 74, No. 5. P. 1629–1633. DOI: 10.1002/1097-0142(19940901)74:5<1629::aid-cncr2820740523>3.0.co;2-l

[33] Osterlund P, Ruotsalainen T, Peuhkuri K, et al. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol. 2004;2(8):696–703. DOI: 10.1016/s1542-3565(04)00293-9

[34] Osterlund P., Ruotsalainen T., Peuhkuri K. et al. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer // Clin. Gastroenterol. Hepatol. 2004. Vol. 2, No. 8. P. 696–703. DOI: 10.1016/s1542-3565(04)00293-9

[35] Pearson AD, Craft AW, Pledger JV, et al. Small bowel function in acute lymphoblastic leukaemia. Arch Dis Child. 1984;59(5):460–465. DOI: 10.1136/adc.59.5.460

[36] Pearson A.D., Craft A.W., Pledger J.V. et al. Small bowel function in acute lymphoblastic leukaemia // Arch. Dis. Child. 1984. Vol. 59, No. 5. P. 460–465. DOI: 10.1136/adc.59.5.460

[37] Pettoello-Mantovani M, Guandalini S, diMartino L, et al. Prospective study of lactose absorption during cancer chemotherapy: feasibility of a yogurt-supplemented diet in lactose malabsorbers. J Pediatr Gastroenterol Nutr. 1995;20(2):189–195. DOI: 10.1097/00005176-199502000-00009

[38] Pettoello-Mantovani M., Guandalini S., diMartino L. et al. Prospective study of lactose absorption during cancer chemotherapy: feasibility of a yogurt-supplemented diet in lactose malabsorbers // J. Pediatr. Gastroenterol. Nutr. 1995. Vol. 20, No. 2. P. 189–195. DOI: 10.1097/00005176-199502000-00009

[39] Bustillo I, Larson H, Saif MW. Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer. JOP. 2009;10(5):576–578.

[40] Bustillo I., Larson H., Saif M.W. Small intestine bacterial overgrowth: an underdiagnosed cause of diarrhea in patients with pancreatic cancer // JOP. 2009. Vol. 10, No. 5. P. 576–578.

[41] Stringer AM, Gibson RJ, Logan RM, et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood). 2009;234(4):430–441. DOI: 10.3181/0810-RM-301

[42] Stringer A.M., Gibson R.J., Logan R.M. et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis // Exp. Biol. Med. (Maywood). 2009. Vol. 234, No. 4. P. 430–441. DOI: 10.3181/0810-RM-301

[43] Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38(7):674–688. DOI: 10.1111/apt.12456

[44] Grace E., Shaw C., Whelan K., Andreyev H.J. Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment // Aliment Pharmacol. Ther. 2013. Vol. 38, No. 7. P. 674–688. DOI: 10.1111/apt.12456

[45] Grigg AP, Angus PW, Hoyt R, Szer J. The incidence, pathogenesis and natural history of steatorrhea after bone marrow transplantation. Bone Marrow Transplant. 2003;31(8):701–703. DOI: 10.1038/sj.bmt.1703911

[46] Grigg A.P., Angus P.W., Hoyt R., Szer J. The incidence, pathogenesis and natural history of steatorrhea after bone marrow transplantation // Bone Marrow Transplant. 2003. Vol. 31, No. 8. P. 701–703. DOI: 10.1038/sj.bmt.1703911

[47] Meta-Analysis Group In Cancer, Lévy E, Piedbois P, Buyse M, et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16(11):3537–3541. DOI: 10.1200/JCO.1998.16.11.3537

[48] Meta-Analysis Group In Cancer, Lévy E., Piedbois P., Buyse M. et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors // J. Clin. Oncol. 1998. Vol. 16, No. 11. P. 3537–3541. DOI: 10.1200/JCO.1998.16.11.3537

[49] Claassen YH, van der Valk MJ, Breugom AJ, et al. Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. Cochrane Database Syst Rev. 2018;11(11):CD012326. DOI: 10.1002/14651858.CD012326.pub2

[50] Claassen Y.H., van der Valk M.J., Breugom A.J. et al. Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer // Cochrane Database Syst. Rev. 2018. Vol. 11, No. 11. P. CD012326. DOI: 10.1002/14651858.CD012326.pub2

[51] Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18(6):1337–1345. DOI: 10.1200/JCO.2000.18.6.1337

[52] Van Cutsem E., Findlay M., Osterwalder B. et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study // J. Clin. Oncol. 2000. Vol. 18, No. 6. P. 1337–1345. DOI: 10.1200/JCO.2000.18.6.1337

[53] Yumuk PF, Aydin SZ, Dane F, et al. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients. Int J Colorectal Dis. 2004;19(6):609–610. DOI: 10.1007/s00384-004-0613-5

[54] Yumuk P.F., Aydin S.Z., Dane F. et al. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients // Int. J. Colorectal. Dis. 2004. Vol. 19, No. 6. P. 609–610. DOI: 10.1007/s00384-004-0613-5

[55] Tomita Y, Moldovan M, Chang Lee R, et al. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. Cochrane Database Syst Rev. 2020;11(11):CD012078. DOI: 10.1002/14651858.cd012078.pub2

[56] Tomita Y., Moldovan M., Chang Lee R. et al. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma // Cochrane Database Syst. Rev. 2020. Vol. 11, No. 11. P. CD012078. DOI: 10.1002/14651858.cd012078.pub2

[57] Ramesh M, Ahlawat P, Srinivas NR. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010;24(1):104–123. DOI: 10.1002/bmc.1345

[58] Ramesh M., Ahlawat P., Srinivas N.R. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives // Biomed. Chromatogr. 2010. Vol. 24, No. 1. P. 104–123. DOI: 10.1002/bmc.1345

[59] Wulaningsih W, Wardhana A, Watkins J, et al. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. Cochrane Database Syst Rev. 2016;2:CD008593. DOI: 10.1002/14651858.CD008593.pub3

[60] Wulaningsih W., Wardhana A., Watkins J. et al. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer // Cochrane Database Syst. Rev. 2016. Vol. 2. P. CD008593. DOI: 10.1002/14651858.CD008593.pub3

[61] Clarke SJ, Yip S, Brown C, et al. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. Eur J Cancer. 2011;47(12):1826–1836. DOI: 10.1016/j.ejca.2011.04.024

[62] Clarke S.J., Yip S., Brown C. et al. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected] // Eur. J. Cancer. 2011. Vol. 47, No. 12. P. 1826–1836. DOI: 10.1016/j.ejca.2011.04.024

[63] Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51–63. DOI: 10.1177/1758834009355164

[64] Stein A., Voigt W., Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management // Ther. Adv. Med. Oncol. 2010. Vol. 2, No. 1. P. 51–63. DOI: 10.1177/1758834009355164

[65] Chen E, Abu-Sbeih H, Thirumurthi S, et al. Clinical characteristics of colitis induced by taxane-based chemotherapy. Ann Gastroenterol. 2020;33(1):59–67. DOI: 10.20524/aog.2019.0431

[66] Chen E., Abu-Sbeih H., Thirumurthi S. et al. Clinical characteristics of colitis induced by taxane-based chemotherapy // Ann. Gastroenterol. 2020. Vol. 33, No. 1. P. 59–67. DOI: 10.20524/aog.2019.0431

[67] Cherny NI. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J Pain Symptom Manage. 2008;36(4):413–423. DOI: 10.1016/j.jpainsymman.2007.10.007

[68] Cherny N.I. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review // J. Pain Symptom Manage. 2008. Vol. 36, No. 4. P. 413–423. DOI: 10.1016/j.jpainsymman.2007.10.007

[69] Shaikh DH, Baiomi A, Mehershahi S, et al. Paclitaxel-induced bowel perforation: a rare cause of acute abdomen. Case Rep Gastroenterol. 2020;14(3):687–694. DOI: 10.1159/000510131

[70] Shaikh D.H., Baiomi A., Mehershahi S. et al. Paclitaxel-induced bowel perforation: a rare cause of acute abdomen // Case Rep. Gastroenterol. 2020. Vol. 14, No. 3. P. 687–694. DOI: 10.1159/000510131

[71] Aapro M, Tjulandin S, Bhar P, Gradishar W. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis. Breast. 2011;20(5):468–474. DOI: 10.1016/j.breast.2011.07.005

[72] Aapro M., Tjulandin S., Bhar P., Gradishar W. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis // Breast. 2011. Vol. 20, No. 5. P. 468–474. DOI: 10.1016/j.breast.2011.07.005

[73] Dranitsaris G, Yu B, King J, et al. Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective. Clinicoecon Outcomes Res. 2015;7:249–256. DOI: 10.2147 / CEOR.S82194

[74] Dranitsaris G., Yu B., King J. et al. Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective // Clinicoecon. Outcomes Res. 2015. Vol. 7. P. 249–256. DOI: 10.2147 / CEOR.S82194

[75] De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154. DOI: 10.1016/S0140-6736(10)61389-X

[76] De Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial // Lancet. 2010. Vol. 376, No. 9747. P. 1147–1154. DOI: 10.1016/S0140-6736(10)61389-X

[77] Nieuweboer AJ, de Graan AM, Hamberg P, et al. Effects of budesonide on cabazitaxel pharmacokinetics and cabazitaxel-induced diarrhea: a randomized, open-label multicenter phase II study. Clin Cancer Res. 2017;23(7):1679–1683. DOI: 10.1158/1078-0432.CCR-16-2110

[78] Nieuweboer A.J., de Graan A.M., Hamberg P. et al. Effects of budesonide on cabazitaxel pharmacokinetics and cabazitaxel-induced diarrhea: a randomized, open-label multicenter phase II study // Clin. Cancer Res. 2017. Vol. 23, No. 7. P. 1679–1683. DOI: 10.1158/1078-0432.CCR-16-2110

[79] Venkatesh P, Kasi A. Anthracyclines. In: StatPearls. Treasure Island (FL). StatPearls Publishing; 2021.

[80] Venkatesh P., Kasi A. Anthracyclines [Internet] // StatPearls. Treasure Island (FL). StatPearls Publishing, 2021.

[81] McQuade RM, Stojanovska V, Abalo R, et al. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol. 2016;7:414. DOI: 10.3389/fphar.2016.00414

[82] McQuade R.M., Stojanovska V., Abalo R. et al. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments // Front. Pharmacol. 2016. Vol. 7. P. 414. DOI: 10.3389/fphar.2016.00414

[83] Pessi MA, Zilembo N, Haspinger ER, et al. Targeted therapy-induced diarrhea: A review of the literature. Crit Rev Oncol Hematol. 2014;90(2):165–179. DOI: 10.1016/j.critrevonc.2013.11.008

[84] Pessi M.A., Zilembo N., Haspinger E.R. et al. Targeted therapy-induced diarrhea: A review of the literature // Crit. Rev. Oncol. Hematol. 2014. Vol. 90, No. 2. P. 165–179. DOI: 10.1016/j.critrevonc.2013.11.008

[85] Secombe KR, Van Sebille YZA, Mayo BJ, et al. Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: potential role of the microbiome. Integr Cancer Ther. 2020;19:1534735420928493. DOI: 10.1177/1534735420928493

[86] Secombe K.R., Van Sebille Y.Z.A., Mayo B.J. et al. Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: potential role of the microbiome // Integr. Cancer Ther. 2020. Vol. 19. P. 1534735420928493. DOI: 10.1177/1534735420928493

[87] Yang JC, Reguart N, Barinoff J, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):729–736. DOI: 10.1586/era.13.31

[88] Yang J.C., Reguart N., Barinoff J. et al. Diarrhea associated with afatinib: an oral ErbB family blocker // Expert. Rev. Anticancer Ther. 2013. Vol. 13, No. 6. P. 729–736. DOI: 10.1586/era.13.31

[89] Peterson ME. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer. 2013;21(8):2341–2349. DOI: 10.1007/s00520-013-1826-3

[90] Peterson M.E. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial // Support Care Cancer. 2013. Vol. 21, No. 8. P. 2341–2349. DOI: 10.1007/s00520-013-1826-3

[91] Chan DLH, Segelov E, Wong RS, et al. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev. 2017;6(6):CD007047. DOI: 10.1002/14651858.CD007047.pub2

[92] Chan D.L.H., Segelov E., Wong R.S. et al. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer // Cochrane Database Syst. Rev. 2017. Vol. 6, No. 6. P. CD007047. DOI: 10.1002/14651858.CD007047.pub2

[93] Sim EH, Yang IA, Wood-Baker R, et al. Gefitinib for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2018;1(1):CD006847. DOI: 10.1002/14651858.CD006847.pub2

[94] Sim E.H., Yang I.A., Wood-Baker R. et al. Gefitinib for advanced non-small cell lung cancer // Cochrane Database Syst. Rev. 2018. Vol. 1, No. 1. P. CD006847. DOI: 10.1002/14651858.CD006847.pub2

[95] Greenhalgh J, Boland A, Bates V, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2021;3(3):CD010383. DOI: 10.1002/14651858.CD010383.pub3

[96] Greenhalgh J., Boland A., Bates V. et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer // Cochrane Database Syst. Rev. 2021. Vol. 3, No. 3. P. CD010383. DOI: 10.1002/14651858.CD010383.pub3

[97] Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3342–3350. DOI: 10.1200/JCO.2012.46.1764

[98] Yang J.C., Hirsh V., Schuler M. et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations // J. Clin. Oncol. 2013. Vol. 31, No. 27. P. 3342–3350. DOI: 10.1200/JCO.2012.46.1764

[99] Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–222. DOI: 10.1016/S1470-2045(13)70604-1

[100] Wu Y.L., Zhou C., Hu C.P. et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial // Lancet Oncol. 2014. Vol. 15, No. 2. P. 213–222. DOI: 10.1016/S1470-2045(13)70604-1

[101] Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004;22(5):777–784. DOI: 10.1200/JCO.2004.08.001

[102] Giaccone G., Herbst R.S., Manegold C. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1 // J. Clin. Oncol. 2004. Vol. 22, No. 5. P. 777–784. DOI: 10.1200/JCO.2004.08.001

[103] Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004;22(5):785–794. DOI: 10.1200/JCO.2004.07.215

[104] Herbst R.S., Giaccone G., Schiller J.H. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2 // J. Clin. Oncol. 2004. Vol. 22, No. 5. P. 785–794. DOI: 10.1200/JCO.2004.07.215

[105] Wu YL, Saijo N, Thongprasert S, et al. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer. 2017;104:119–125. DOI: 10.1016/j.lungcan.2016.11.022

[106] Wu Y.L., Saijo N., Thongprasert S. et al. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC // Lung Cancer. 2017. Vol. 104. P. 119–125. DOI: 10.1016/j.lungcan.2016.11.022

[107] Wu YL, Fukuoka M, Mok TS, et al. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer. 2013;81(2):280–287. DOI: 10.1016/j.lungcan.2013.03.004

[108] Wu Y.L., Fukuoka M., Mok T.S. et al. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study // Lung Cancer. 2013. Vol. 81, No. 2. P. 280–287. DOI: 10.1016/j.lungcan.2013.03.004

[109] Thongprasert S, Duffield E, Saijo N, et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011;6(11):1872–1880. DOI: 10.1097/JTO.0b013e31822adaf7

[110] Thongprasert S., Duffield E., Saijo N. et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS) // J. Thorac. Oncol. 2011. Vol. 6, No. 11. P. 1872–1880. DOI: 10.1097/JTO.0b013e31822adaf7

[111] Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017;28(10):2443–2450. DOI: 10.1093/annonc/mdx359

[112] Shi Y.K., Wang L., Han B.H. et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study // Ann. Oncol. 2017. Vol. 28, No. 10. P. 2443–2450. DOI: 10.1093/annonc/mdx359

[113] Chen YM, Tsai CM, Fan WC, et al. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older. J Thorac Oncol. 2012;7(2):412–418. DOI: 10.1097/JTO.0b013e31823a39e8

[114] Chen Y.M., Tsai C.M., Fan W.C. et al. Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older // J. Thorac. Oncol. 2012. Vol. 7, No. 2. P. 412–418. DOI: 10.1097/JTO.0b013e31823a39e8

[115] Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246. DOI: 10.1016/S1470-2045(11)70393-X

[116] Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial // Lancet Oncol. 2012. Vol. 13, No. 3. P. 239–246. DOI: 10.1016/S1470-2045(11)70393-X

[117] Heigener DF, Deppermann KM, Pawel JV, et al. Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer. Lung Cancer. 2014;84(1):62–66. DOI: 10.1016/j.lungcan.2014.01.024

[118] Heigener D.F., Deppermann K.M., Pawel J.V. et al. Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer // Lung Cancer. 2014. Vol. 84, No. 1. P. 62–66. DOI: 10.1016/j.lungcan.2014.01.024

[119] Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2012;13(11):1161–1170. DOI: 10.1016/S1470-2045(12)70412-6

[120] Lee S.M., Khan I., Upadhyay S. et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial // Lancet Oncol. 2012. Vol. 13, No. 11. P. 1161–1170. DOI: 10.1016/S1470-2045(12)70412-6

[121] Lee A, Arasaratnam M, Chan DLH, et al. Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Cochrane Database Syst Rev. 2020;5(5):CD013238. DOI: 10.1002/14651858.CD013238.pub2

[122] Lee A., Arasaratnam M., Chan D.L.H. et al. Anti-epidermal growth factor receptor therapy for glioblastoma in adults // Cochrane Database Syst. Rev. 2020. Vol. 5, No. 5. P. CD013238. DOI: 10.1002/14651858.CD013238.pub2

[123] Jiao J, Li C, Yu G, et al. Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites. World J Surg Oncol. 2020;18(1):180. DOI: 10.1186/s12957-020-01956-y

[124] Jiao J., Li C., Yu G. et al. Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites // World J. Surg. Oncol. 2020. Vol. 18, No. 1. P. 180. DOI: 10.1186/s12957-020-01956-y

[125] Baratelli C, Zichi C, Di Maio M, et al. A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. Crit Rev Oncol Hematol. 2018;122:21–29. DOI: 10.1016/j.critrevonc.2017.12.010

[126] Baratelli C., Zichi C., Di Maio M. et al. A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients // Crit. Rev. Oncol. Hematol. 2018. Vol. 122. P. 21–29. DOI: 10.1016/j.critrevonc.2017.12.010

[127] Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119–iv142. DOI: 10.1093/annonc/mdx225

[128] Haanen J.B.A.G., Carbonnel F., Robert C. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2017. Vol. 28, No. suppl_4. P. iv119–iv142. DOI: 10.1093/annonc/mdx225

[129] Loranskaya ID. Diareya pri zabolevaniyakh organov pishchevareniya [Internet]. Lechashchiy vrach. 2007. Available from: https://www.lvrach.ru/2007/06/4535302. Accessed: Aug 13, 2021. (In Russ.)

[130] Лоранская И.Д. Диарея при заболеваниях органов пищеварения [Электронный ресурс] // Журнал лечащий врач. 2007. Режим доступа: https://www.lvrach.ru/2007/06/4535302. Дата обращения: 13.08.2021.

[131] Goldkuhle M, Dimaki M, Gartlehner G, et al. Nivolumab for adults with Hodgkin’s lymphoma (a rapid review using the software RobotReviewer). Cochrane Database Syst Rev. 2018;7(7):CD012556. DOI: 10.1002/14651858.CD012556.pub2

[132] Goldkuhle M., Dimaki M., Gartlehner G. et al. Nivolumab for adults with Hodgkin’s lymphoma (a rapid review using the software RobotReviewer) // Cochrane Database Syst. Rev. 2018. Vol. 7, No. 7. P. CD012556. DOI: 10.1002/14651858.CD012556.pub2

[133] Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkmate 205 trial. J Clin Oncol. 2018;36(14):1428–1439. DOI: 10.1200/JCO.2017.76.0793

[134] Armand P., Engert A., Younes A. et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkmate 205 trial // J. Clin. Oncol. 2018. Vol. 36, No. 14. P. 1428–1439. DOI: 10.1200/JCO.2017.76.0793

[135] Slangen RM, van den Eertwegh AJ, van Bodegraven AA, de Boer NKh. Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab. World J Gastrointest Pharmacol Ther. 2013;4(3):80–82. DOI: 10.4292/wjgpt.v4.i3.80

[136] Slangen R.M., van den Eertwegh A.J., van Bodegraven A.A., de Boer N.Kh. Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab // World J. Gastrointest. Pharmacol. Ther. 2013. Vol. 4, No. 3. P. 80–82. DOI: 10.4292/wjgpt.v4.i3.80

[137] De Felice KM, Gupta A, Rakshit S, et al. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res. 2015;25(4):321–327. DOI: 10.1097/CMR.0000000000000165

[138] De Felice K.M., Gupta A., Rakshit S. et al. Ipilimumab-induced colitis in patients with metastatic melanoma // Melanoma Res. 2015. Vol. 25, No. 4. P. 321–327. DOI: 10.1097/CMR.0000000000000165

[139] Mocellin S, Goodwin A, Pasquali S. Risk-reducing medications for primary breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2019;4(4):CD012191. DOI: 10.1002/14651858.CD012191.pub2

[140] Mocellin S., Goodwin A., Pasquali S. Risk-reducing medications for primary breast cancer: a network meta-analysis // Cochrane Database Syst. Rev. 2019. Vol. 4, No. 4. P. CD012191. DOI: 10.1002/14651858.CD012191.pub2

[141] Lee HY, Lee YH, Kim MJ, Kim HK. Secondary prophylaxis of docetaxel induced diarrhea with loperamide: case report. J Korean Med Sci. 2013;28(10):1549–1551. DOI: 10.3346/jkms.2013.28.10.1549

[142] Lee H.Y., Lee Y.H., Kim M.J., Kim H.K. Secondary prophylaxis of docetaxel induced diarrhea with loperamide: case report // J. Korean Med. Sci. 2013. Vol. 28, No. 10. P. 1549–1551. DOI: 10.3346/jkms.2013.28.10.1549

[143] Lawrie TA, Green JT, Beresford M, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev. 2018;1(1):CD012529. DOI: 10.1002/14651858.CD012529.pub2

[144] Lawrie T.A., Green J.T., Beresford M. et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers // Cochrane Database Syst. Rev. 2018. Vol. 1, No. 1. P. CD012529. DOI: 10.1002/14651858.CD012529.pub2

RIGHTS & PERMISSIONS

Sychev D.A., Ostroumova O.D., Ziganshina L.E., Filippova A.V.